Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print Scleroderma Outlook Improves as Survival Increases

Scleroderma Outlook Improves as Survival Increases

July 13, 2007

Washington, D.C. -- Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further.

Scleroderma, a rare autoimmune disorder of unknown origin, results when collagen builds up in the body's connective tissue and causes thickening of the skin. In the chronic and often progressive systemic form, scleroderma causes stiff joints and hardening of the internal organs and blood vessels.




In the July issue of the journal Annals of the Rheumatic Diseases, Georgetown University Medical Center professor Virginia Steen, M.D., studied 2,000 patients with scleroderma (also known as systemic sclerosis) treated between 1972 and 2001 at the University of Pittsburgh and found that 10-year survival steadily improved over those years by 12 percent-- from 54 percent to 66 percent.

"This is really good progress, which we hope to improve upon," said Steen, a leading expert on the disorder who has helped make Georgetown University Hospital a national treatment center for scleroderma. In the 1980s, while at the University of Pittsburgh, she developed a natural history database of scleroderma patients and this database has continued to evolve into the largest in the United States.

The reason overall mortality has dropped, Steen says, is partly because a class of medications, angiotensin converting enzyme (ACE) inhibitors became available which dramatically improved the treatment of renal crisis. Renal crisis used to be almost always fatal and now it is a very treatable complication of scleroderma, she said.

Now pulmonary arterial hypertension and pulmonary fibrosis, a condition that is traditionally the second-most frequent cause of death, is responsible for most of the mortality, but these conditions may be increasingly treatable, she said. Patients may develop either disorder, or both.

"Before, it was kidney and then lung disorders that affected most of our patients, and now that we have successfully treated the kidneys, mortality due to lung disease has become the issue," Steen said. "We are working on ways to use the newer medications to help treat these disorders, hoping to further improve overall survival."

While all scleroderma-related disorders are believed to affect as many as 900,000 people in the United States, only between 40,000 and 165,000 are diagnosed with systemic scleroderma, according to the National Institutes of Health (NIH). Like all scleroderma disorders, systemic scleroderma affects more women than men, and varies in severity.

In this study, Steen collaborated with co-author Thomas Medsger, M.D., professor of medicine at the University of Pittsburgh to study patients with systemic scleroderma enrolled in the registry. They studied patients evaluated at the University of Pittsburgh between 1972 and 2001, dividing them into five-year time periods, depending on when they were seen.

They found survival improved in each of the five-year periods, and that the frequency of death due to renal crisis significantly decreased over the 30 years, from 42 percent to 6 percent. But the proportion of patients who died from pulmonary fibrosis increased from 6 percent to 33 percent, Steen said. The frequency of pulmonary hypertension also increased, but there was no change in gastrointestinal and heart-related deaths.

"Use of ACE inhibitors made all the difference in saving patients from renal failure, and now it is important that physicians use drugs now available to treat lung disorders and researchers continue to search for new therapies," Steen said.

Georgetown University Medical Center



Related Scleroderma News Articles Scleroderma News and Current Scleroderma Events RSS Scleroderma News and Current Scleroderma Events RSS
Dartmouth researchers discover gene signatures for scleroderma
Distinct genetic profiles can discern different groups of patients with scleroderma, a vexing autoimmune disease in which the body turns against itself, Dartmouth Medical School researchers report.

UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.

Researchers show that fibrosis can be stopped, cured and reversed
University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.

Green tea may help prevent autoimmune diseases
Green tea may help protect against autoimmune disease, Medical College of Georgia researchers say.

Space Technology Benefits Medical Community
A small group of APL researchers, in collaboration with physicians from the Johns Hopkins Scleroderma Center in Baltimore, developed and recently completed initial trials for a miniature device to help physicians characterize Raynaud's disease and measure treatment effectiveness.

Rice breakthrough could prevent multiple fibrotic diseases
A scientific breakthrough at Rice University could lead to the first treatment that prevents the build-up of deadly scar tissue in a broad class of diseases that account for an estimated 45 percent of U.S. deaths each year.

Cancer drug may be remedy for rheumatoid arthritis, Stanford study finds
The potent cancer drug Gleevec, used to combat leukemia and some gastrointestinal cancers, may be useful in treating rheumatoid arthritis.

First different black/white mechanism in pulmonary fibrosis/scleroderma identified
Of the more than 40,000 persons who die each year in the U.S. from pulmonary fibrosis, the mortality rate among African-Americans is twice as high Caucasians.
More Scleroderma News Articles


Scleroderma: The Proven Therapy that Can Save Your Life
by Henry Scammell

Scleroderma, which affects as many as 400,000 Americans, starts off like skin cancer but is far more deadly. This new edition is updated with new information about the best therapy for this disease, including the results of the landmark first, and a new, second clinical trial of the only therapy to report reversal and remission of this deadly...



The Scleroderma Book: A Guide for Patients and Families
by Maureen D. Mayes

The Scleroderma Book has long been considered the leading source of information for patients suffering with this disease. Now comes the Second Edition of this highly respected volume, extensively revised by Maureen Mayes, M.D., the leading authority in this field. Writing specifically for patients and their families, Dr. Mayes draws on her extensive experience treating scleroderma to provide...



It's Not Just Growing Pains: A Guide to Childhood Muscle, Bone and Joint Pain, Rheumatic Diseases, and the Latest Treatments
by Thomas J. A. Lehman

Arthritis is usually considered a disease of older adults, but nearly 300,000 children in the United States suffer from some form of arthritis or rheumatic disease, such as juvenile arthritis (JRA), fibromyalgia, chronic fatigue, systemic lupus erythematosus, scleroderma, or Kawasaki disease. Yet until now very little information has been available to guide parents and doctors in properly...



Connective Tissue Diseases: Holistic Therapy Options--Sjoegren¿s Syndrome; Systemic Sclerosis - Scleroderma; Systemic Lupus Erythematosus; Discoid Lupus Erythematosus; Secondary and Primary Raynaud¿s phenomenon; Raynaud¿s Disease; Polymyositis ¿ Dermatomyositis
by Hannelore Helbing-Sheafe

Hannelore Helbing-Sheafe’s constant struggle with her health was a powerful motivator to investigate possible ways to help herself and others. The focus of her practice was always on finding the cause of the problem and instructing patients in using correct nutrients and/or natural medicine and therapy to correct and reverse existing health problems. Her main focus has been to seek...



The First Year: Scleroderma: An Essential Guide for the Newly Diagnosed (The First Year Series)
by Karen Gottesman

Scleroderma—a chronic autoimmune condition that causes hardening, thickening, or tightening of the skin and attacks the heart, lungs, kidneys, and gastrointestinal tract—is extraordinarily difficult to diagnose and can take a huge toll on the psychological well-being of the individual. From the first moment of her diagnosis, author Karen Gottesman took charge and educated herself on...



A Place to Go: How Scleroderma Changed My Life
by Maureen Taylor

For two years, author Maureen Taylor’s health slowly deteriorated as she was pursued by a relentless but mysterious illness. It disfigured her face, turned her hands into claws, and left her skin as hard as a board. In 1988, she finally learned the name of the disease that was ravaging her body: scleroderma. Scleroderma was more than just a disease—it was also Taylor’s teacher. It taught her...



The Official Patient's Sourcebook on Scleroderma
by James N. Parker, Icon Health Publications

This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to scleroderma (also Familial Progressive Systemic Sclerosis; Morphea;...



Scleroderma, An Issue of Rheumatic Disease Clinics (The Clinics: Internal Medicine)
by Fredrick M. Wigley

Scleroderma is unique among our rheumatic diseases both in its clinical expression and its resistance to recovery when using our usual anti-inflammatory medications. The reason for this difference is now becoming apparent as the biology of the scleroderma process is better understood. It is now recognized that the disease expression is quite heterogeneous and that several different clinical but...



Voices of Scleroderma
by International Scleroderma Network

“I highly recommend this book for patients, caregivers, and medical professionals who want quality medical information and support for scleroderma and related illnesses. “Access to high quality reliable modern information is crucial to patient well-being and outcomes. The realization that ‘you ARE NOT alone’ has therapeutic value in its own right. “The nonprofit International Scleroderma...

Low-dose UVA-1 may markedly improve extragenital lichen sclerosus. (Even Extensive Long-Standing Disease).(phototherapy): An article from: Skin & Allergy News
by Bruce Jancin

This digital document is an article from Skin & Allergy News, published by International Medical News Group on March 1, 2002. The length of the article is 849 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com